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Abstract
Background: Spontaneous reporting of adverse drug reactions (ADRs) is an important method for
pharmacovigilance, but under-reporting and poor quality of reports are major limitations. The aim of this study was
to evaluate if repeated one-page ADR information letters affect (i) the reporting rate of ADRs and (ii) the quality of
the ADR reports.
Methods: All 151 primary healthcare units in the Region Västra Götaland, Sweden, were randomly allocated (1:1) to
an intervention (n = 77) or a control group (n = 74). The intervention consisted of one-page ADR information
letters administered at three occasions during 2008 to all physicians and nurses in the intervention units. The
number of ADR reports received from the 151 units was registered, as was the quality of the reports, which was
defined as high if the ADR was to be reported according to Swedish regulations, that is, if the ADR was (i) serious,
(ii) unexpected, and/or (iii) related to the use of new drugs and not labelled as common in the Summary of
Product Characteristics. A questionnaire was administered to evaluate if the ADR information letter had reached
the intended recipient.
Results: Before the intervention, no significant differences in reporting rate or number of high quality reports
could be detected between the randomization groups. In 2008, 79 reports were sent from 37 intervention units
and 52 reports from 30 control units (mean number of reports per unit ± standard deviation: 1.0 ± 2.5 vs. 0.7 ± 1.2,
P = 0.34). The number of high quality reports was higher in intervention units than in control units (37 vs. 15
reports, 0.5 ± 0.9 vs. 0.2 ± 0.6, P = 0.048). According to the returned questionnaires (n = 1,292, response rate 57%),
more persons in the intervention than in the control group had received (29% vs. 19%, P < 0.0001) and read (31%
vs. 26%, P < 0.0001) an ADR information letter.
Conclusions: This study suggests that repeated ADR information letters to physicians and nurses do not increase
the ADR reporting rate, but may increase the number of high quality reports.
Background
Clinical trials contribute greatly to knowledge on drug
safety. However, uncommon adverse drug reactions
(ADRs) and ADRs in certain patient groups not included
in clinical trials, e.g. children and older people with many
concomitant diseases and medications, cannot be
expected to be detected in these trials. Hence post-
marketing surveillance on effects of drugs in clinical
practice is essential and spontaneous reporting of ADRs
has shown to be an important method to increase drug
safety knowledge [1]. In Sweden, physicians, dentists, and
nurses are obliged to report (i) serious ADRs, (ii) ADRs
not mentioned in the summary of product characteristics
(SPC), (iii) ADRs related to the use of new drugs (≤ 2
years on the market) except those labelled as common in
the SPC, and (iv) ADRs which incidence seems to
increase [2]. Reports concerning the three first points
may be most important as far as pharmacovigilance is
concerned since they may result in relevant ADR signals,
defined as reported information on a possible causal rela-
tionship between a drug and an adverse event, the rela-
tionship being unknown or incompletely documented
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should be focused on such ADRs.
A major limitation of the spontaneous reporting system
is that only a small part of all ADRs are reported [4]. A
review shows that factors associated with under-reporting
include ignorance (only severe ADRs need to be reported),
diffidence (fear of appearing ridiculous for reporting
merely suspected ADRs), lethargy (e.g. lack of interest or
time), indifference (one case from an individual doctor
does not contribute to medical knowledge), insecurity
(causality between a drug and an adverse event is hard to
determine), and complacency (only safe drugs are allowed
on the market) [5]. Hence, methods to improve the report-
ing rate of ADRs could address one or more of these
obstacles. Ignorance, diffidence, indifference, insecurity,
and complacency can be defeated by education and distri-
bution of drug safety information; methods which have
been shown to increase the ADR reporting rate [6-9]. Edu-
cation may also have positive effects on lethargy, but avail-
ability of clinical research assistants may be more effective
as far as this obstacle is concerned [10]. Methods which
reward individual reporters could also be interesting alter-
natives to increase the reporting, e.g. lottery tickets [11] or
detailed feedback [12]. In addition, allowing other cate-
gories of reporters could be beneficial, e.g. nurses [13] and
patients/consumers [14].
The methods mentioned above differ in efforts and
costs, and there is a need for additional easily managed
methods to improve ADR reporting which can be main-
tained over time without too much efforts or costs. Such
a method may be distribution of written information. We
have previously shown that such information via e-mail
had no apparent effect on the reporting of ADRs,
although an increase in the reporting rate in general was
noted [8]. From our own experience, we know that
e-mails are often overlooked and thus the effect on infor-
mation via this route, although cheap and easily mana-
ged, may have limited effects. In the present study, we
hypothesized that written information in the format of a
letter administered to health care personnel may have a
larger impact on the reporting rate. Indeed, a previous
time series analysis has shown positive effects on report-
ing rate when an ADR bulletin was administered quar-
terly to physicians [7]. To the best of our knowledge,
however, the impact of written ADR information letters
administered to healthcare personnel on reporting of
ADRs has previously not been evaluated in a randomized
controlled study. Moreover, knowledge lacks on the
impact of such information on which ADRs are reported,
an aspect which is important since some ADRs are more
valuable in the pharmacovigilance work, as previously
mentioned. The aim of the present study was thus to
evaluate if repeated ADR information letters adminis-
tered to physicians and nurses in primary healthcare
units through the secretary of the unit can affect (i) the
reporting rate of ADRs and (ii) the quality of the ADR
reports.
Methods
All 151 primary healthcare units in the Region Västra
Götaland, Sweden, were randomly allocated (1:1) to an
intervention or a control group. A primary healthcare
unit generally consists of several general practitioners
and nurses who serve patients in a limited geographic
area, although patients may choose to attend another
unit at their convenience. The units were expected to
report ADRs to various extents. Furthermore, in 2007, 63
of the units were included in a randomized controlled
trial of repeated e-mails with ADR information [8].
Hence, the allocation was stratified according to number
of ADR reports in 2007 and whether or not the unit had
received the repeated drug safety e-mails. A person not
involved in the study and without knowledge about the
study protocol performed the randomization procedure.
The intervention consisted of a one-page ADR informa-
tion letter which was sent to the secretary of each unit
with an instruction letter that it should be distributed to
all physicians and nurses at the unit. The number of letters
supplied for each unit was estimated based on publicly
available information on the staffing of the units, and the
secretary was instructed to copy the information letter if
more letters were needed.
The ADR information letters were constructed by the
authors of this study, who, at the time of the study, all
worked at the regional pharmacovigilance centre which
serves the Region Västra Götaland. The letters consisted
of (i) the heading “ADR Information Letter”, (ii) a current
case report of an ADR and (iii) instructions on what and
how to report [see Additional files 1, 2 and 3]. The letters
were sent in January, May, and September 2008.
ADR reports from the included primary healthcare units
were extracted from the SWEdish Drug Information Sys-
tem (SWEDIS), the Swedish ADR database where all ADR
reports are registered, after being assessed for e.g. causality
and seriousness according to the definitions by the World
Health Organization [3]. The number of reports from
each primary healthcare unit was thus registered, as was
the quality of the report, which was defined as high if the
ADR was to be reported according to the Swedish regula-
tions on ADR reporting, that is, if the ADR was (i) serious,
(ii) unexpected, that is, not labelled in the SPC, and/or (iii)
related to the use of new drugs (≤ 2 years on the market)
and not labelled as common in the SPC. Trained and
experienced staff working at the regional pharmacovigi-
lance centre conducted the assessments.
In January 2009, questionnaires were supplied to the
secretaries of the intervention and the control units, to be
distributed to all physicians and nurses, using a procedure
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included questions as to whether the ADR information let-
ter had been received and read [see Additional file 4]. The
questionnaire was to be answered anonymously, and ques-
tionnaires administered to intervention and control units
differed in the first letter of one word (capital or lower
case), in order to distinguish the origin of the returned
questionnaire (intervention or control unit).
Statistics
Statistical analyses were conducted using SPSS 14.0.
Mann-Whitney test was used for between-group compar-
isons of number of reports per unit. A P-value < 0.05 was
considered significant. Where appropriate mean (stan-
dard deviation) and median (interquartile range [IQR])
was used.
Results
A total of 77 primary healthcare units were randomly allo-
cated to the intervention group, and the remaining
74 units to the control group. As for characteristics of the
randomized units, the median (IQR) numbers of physi-
cians and nurses working at intervention units were 6 (4-
7) and 9 (7-13), respectively. The corresponding numbers
for the control units were 5 (4-7) and 9 (6-13), respec-
tively. The reporting rate the year before the intervention
was 62 reports from 32 (42%) intervention units, and 55
reports from 31 (42%) control units (mean number of
reports per unit ± standard deviation (SD): 0.8 ± 1.4
vs.0.74 ± 1.1, P = 0.93). The number of reports per unit
ranged from 0 to 8 (intervention) and 0 to 4 (control).
There was no statistically significant difference in the
number of high quality reports reported by the interven-
tion and control units (n = 30 vs. n = 19, 0.4 ± 0.8 vs.
0.3 ± 0.6, P = 0.21).
In 2008, a total of 131 reports were received from the
participating healthcare units; 79 reports were sent from
37 intervention units and 52 reports from 30 control units
(mean number of reports per unit ± SD: 1.0 ± 2.5 vs. 0.7 ±
1.2, P = 0.34, Table 1). The number of reports per unit
ranged from 0 to 20 (intervention group) and 0 to 7 (con-
trol group).
The number of high quality reports was higher in inter-
vention units than in control units (37 vs. 15 reports,
mean number of reports per unit ± SD: 0.5 ± 0.9 vs. 0.2 ±
0.6, P = 0.048, Table 1). Summarized, these reports (n =
52, 40% of all reports) concerned (i) serious ADRs (n = 16
[12% of all reports]), (ii) unexpected ADRs (n = 33 [25% of
all reports]), and/or (iii) new drugs (n = 11 [8% of all
reports]), as presented in Table 1. The high quality reports
concerned 44 substances. Varenicline, acetylsalicylic acid,
enalapril, citalopram, and levonorgestrel were reported
more than once, and the details of the reports concerning
these substances are described in Table 2.
A total of 845 physicians and 1,423 nurses worked in the
primary healthcare units. A total of 1,292 questionnaires
were duly filled and returned. The response rate was
therefore 57% (physicians, n = 556; nurses, n = 711; other
professions, n = 17 [these were not intended to receive
and respond to the questionnaire, but did so anyway]). A
total of 300 respondents reported having received at least
one ADR information letter during 2008 (23%), and 362
(28%) had read at least one ADR information letter during
the year. More persons in the intervention group than in
the control group had received (29% vs. 19%, P < 0.0001)
and read (31% vs. 26%, P < 0.0001) an ADR information
letter during 2008. In the intervention group, more physi-
cians than nurses had received (36% vs. 28%, P < 0.015)
but not read (36% vs. 37%, P = 0.89) the ADR information
letter.
Table 1 Description of the reporting of adverse reactions from the randomized primary healthcare units in 2008
Control units
(n = 74)
Intervention units
(n = 77)
P-value
Total number of reports 52 79
Number of reporting units (% of all units) 30 (40.5%) 37 (48.1%)
Mean number of reports per unit (± SD)** 0.70 ± 1.21 1.03 ± 2.46 0.34
Total number of high quality reports (% of all reports)* 15 (29%) 37 (48%)
Serious 4 12
Unexpected 13 20
New drug and not
common ADR*
47
Mean number of high quality reports per unit (± SD) 0.20 ± 0.57 0.47 ± 0.94 0.048
*A high quality report was defined as a report concerning an ADR which should be reported according to Swedish regulations, that is, an ADR which was (i)
serious, (ii) unexpected, and/or (iii) related to the use of new drugs and not labelled as common in the SPC.
**Mean ± SD is presented although the non-parametric Mann Whitney test was used for comparisons between randomization groups, since median (interquartile
range) would provide limited information.
ADR, adverse drug reaction; SD, standard deviation; SPC, summary of product characteristics
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Age
(years)
Sex Suspected
substance/s
Dose ADR diagnosis Serious* Unexpected* New drug and not
common ADR**
Treatment
duration
Time to
ADR onset
Positive
dechallange
Concomitant
medication
Causality
assessment*
55 F Acetylsalicylic acid/
caffeine
500/50
mg
Pruritus N Y N 1 dose Hours NR NR Probable
63 F Acetylsalicylic acid NR Haemorrhagic
gastric ulcer
Y N N NR NR Y Candesartan Possible
80 F Acetylsalicylic acid NR Gastrointestinal
haemorrhage
Y N N 8 weeks 8 weeks Died NR Possible
56 F Citalopram 60 mg Nail disorder N Y N NR NR Medication
continued
Folic acid
Propiomazine
Diazepam
Levothyroxine
Possible
78 F Citalopram
Enalapril
Dextropropoxyphene
Omeprazole
Bendroflumethiazide
20 mg
15 mg
150
mg
20 mg
5m g
Hyponatraemia
Confusion
Y N N NR NR Medication
continued
Dipyridamole
Budesonide/
formoterol
Tiotropium
Cholecalciferol/
calcium
Macrogol,
combinations
Vitamin B-
complex
Paracetamol
Cyanocobalamin
Sodium
picosulfate
Ferrous sulphate
Levothyroxine
Antacids, salt
combination
Acetylcysteine
Possible
38 F Enalapril 5 mg Yawning N Y N 3 weeks Days Y N Possible
69 F Enalapril 20 mg Diplopia N Y N NR NR Medication
continued
N Possible
35 F Levonorgestrel NR Fatigue
Myalgia
NY
Y
N 15 months Days Y Paracetamol
Tramadol
Possible
38 F Levonorgestrel NR Ectopic
pregnancy
Y N N 4 years 4 years Y N Possible
49 M Varenicline 1 mg Thrombophlebitis N Y Y 2 months 2 months NR Atenolol Possible
61 F Varenicline 2 mg Confusion N Y Y 2 weeks NR Y Dipyridamole
Simvastatin
Possible
62 F Varenicline NR Macula-
degeneration
N Y Y 4 months 5 months NR NR Unclassifiable
66 F Varenicline NR Oedema legs Y Y Y 5 weeks 4 weeks N Naproxen
Omeprazole
Folic acid
Possible
*According to the World Health Organization (WHO)[3].
**Concerning new drugs and not labelled as common in the SPC.
ADR, adverse drug reaction; F, female; M, male; N, no; NR, not reported; Y, yes.
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6Discussion
In the present study, no effect of repeated one-page ADR
information letters on the overall reporting rate could be
detected. The results are in contrast to the findings by
Castel et al., who reported an increased reporting rate
after distribution of a drug safety bulletin [7]. One expla-
nation for the divergent findings may be that the meth-
odologies to evaluate differences in reporting rate differ
between the studies; we used a randomized controlled
design whereas Castel et al. used a time series methodol-
ogy. Nevertheless, other interventions may be more useful
when the number of ADR reports is to be increased, such
as education [6,9] or detailed feedback to the reporting
physician [12].
Our results show that more high quality reports were
received from intervention than control units, that is, the
reports more often concerned ADRs which should be
reported according to Swedish regulations. Thus, repeated
ADR information letters may represent a valuable means
to increase the number of reports which should actually be
reported. One may speculate that a combination of such
letters with an educational intervention may be even more
effective as regards this aspect, since the latter also has
been shown beneficial [6]. Indeed, from a pharmacovigi-
lance perspective, it is of importance that ADR reporting is
focused on ADRs which are most likely to contribute to
increased drug safety knowledge. ADR reports concerning
well-known non-serious conditions may thus be of limited
value since these contribute little to ADR signals. On the
contrary, these reports constitute background noise, which
may make detection of ADR signals more difficult at least
as far as statistical signal detection methods within ADR
databases are concerned, e.g. Proportional Reporting Ratios
(PRR) [15] and Bayesian Confidence Propagation Neural
Network (BCPNN) [16].
Varenicline was the most frequently reported substance
in high quality reports. This substance was registered for
smoking cessation in 2006 and thus the reports concerned
a new drug. In addition, these reports also concerned unex-
pected ADRs. Indeed, the majority of high quality reports
concerned unexpected ADRs. This finding may not be sur-
prising since primary healthcare personnel probably
observe serious ADRs less frequently than hospital person-
nel due to the definition of a serious ADR; any untoward
medical occurrence that, at any dose (i) results in death; (ii)
requires inpatient hospitalization or prolongation of exist-
ing hospitalization; (iii) results in persistent or significant
disability/incapacity; or (iv) is life-threatening [3].
Interestingly, 84 out of 151 primary healthcare units
(56%) did not report any ADR during 2008. This finding
supports a high degree of under-reporting [4], and may
indicate that primary healthcare personnel is an important
target for interventions for improved reporting of ADRs.
Significantly more questionnaire responders had
received and read the ADR information letters in the
intervention group. However, the figures were generally
low, indicating that ADR information letters are not prior-
itized reading for healthcare personnel in clinical practice.
Interestingly, many questionnaire responders in the con-
trol units reported having received and read the ADR
information letter. The intervention thus seems to have
spilled over to the control units. Physicians and nurses
may work in more than one primary healthcare unit, that
is, both in the intervention group and in the control
group. Furthermore, the units all belong to the same orga-
nization and information may thus easily pass from one
unit to another. Another explanation for the finding that
the ADR information letters were read by personnel in the
control units is that ADR information from other sources,
e.g. the pharmaceutical industry, may have been adminis-
tered to the primary healthcare during 2008.
An important limitation of the present study is the
small number of reports received from the small num-
ber of primary healthcare units. Indeed, given the avail-
able number of primary healthcare units in the region
and the final results, the power of the present study to
detect differences between the groups ended at 17%.
Another limitation is that our definition of quality of
ADR reports was quite strict and related only to the
Swedish regulations on ADR reporting. Thus, the infor-
mation content of the report as regards other important
aspects were not evaluated, such as factors of importance
for the assessment of the strength of the relationship
between the drug/s and the event/s, i.e. time to ADR
onset, and response to dechallenge and rechallenge.
Conclusions
Repeated ADR information letters to physicians and
nurses was not found to increase the ADR reporting rate,
However, such an intervention may still be favorable
from a pharmacovigilance perspective since it resulted in
an increased number of reports concerning ADRs which
should be reported according to Swedish regulations.
Additional material
Additional file 1: ADR information letter I. The first ADR information
letter sent to physicians and nurses in the intervention units (translated
to English).
Additional file 2: ADR information letter II. The second ADR
information letter sent to physicians and nurses in the intervention units
(translated to English).
Additional file 3: ADR information letter III. The third ADR information
letter sent to physicians and nurses in the intervention units (translated
to English).
Additional file 4: Questionnaire. Questionnaire sent to physicians and
nurses in intervention and control units (translated to English).
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